Thrombocytopoiesis of 21 multiple myeloma patients undergoing single or double transplant regimen was characterized by measuring the level of reticulated platelets and plasma glycocalicin. Since reticulated platelets are an index of thrombopoietic activity and glycocalicin plasma values are related to platelet damage and turnover, it may be possible to perform a novel type of analysis of the thrombopoietic compartment during the mobilizing regimen and during transplantrelated chemotherapy. Patients underwent mobilizing therapy and first transplant. Some randomized patients also underwent a second transplant with mobilized peripheral blood stem cells. The results show that the percentage of reticulated platelets decreased after therapy and then gradually increased in the recovery phase either during first or second transplant. By contrast, the percentage of reticulated platelets increased until day +8 and then gradually decreased during the mobilizing regimen. The glycocalicin index (glycocalicin plasma value normalized for the individual platelet count) increased significantly both during the course of mobilization and after transplant-related chemotherapy when the platelet number was at its nadir. However, the glycocalicin index was more elevated after transplantrelated chemotherapy than after the mobilizing regimen. Our findings suggest that chemotherapy-related thrombocytopenia may be due to a dual mechanism: thrombocytopenia results from decreased platelet production in addition to increased platelet damage and possible destruction.
the RNA content of platelet-rich plasma by flow cytometry. 4 It has been suggested that this can provide a reliable indication of the rate of thrombopoiesis, similar to the use of the erythrocyte reticulocyte count to evaluate erythropoiesis. 4, 5 Several studies have demonstrated the usefulness of evaluation of reticulated platelets to characterize thrombocytopenia [6] [7] [8] [9] [10] [11] [12] [13] or thrombocytosis. 14 Glycocalicin (GC), which is a carbohydrate-rich hydrophilic fragment that can be rapidly cleaved from the extramembranous portion of the ␣-chain of glycoprotein Ib by various proteases, 15, 16 has been proposed as a novel platelet specific marker for platelet membrane injury in vivo. 16 Since GC circulates in plasma and its plasma level is dependent on platelet count, GC index (plasma level normalised for the individual platelet count) has been proposed as a useful parameter for assessment of thrombopoiesis, 16, 17 as well as of platelet turnover. [18] [19] [20] Circulating RP have been described after transplant by Romp et al 8 and by Richards et al. 10 However, these studies were performed in patients undergoing transplantation for solid tumors 8 or mixed hematological malignancies. 10 GC concentration and index have yet to be studied in transplanted patients. In the present study, we evaluated plasma GC concentration and the level of RP in 21 patients with multiple myeloma (MM) undergoing one or two sequential transplants with mobilized PBSC, in order to better characterize the thrombocytopenia which occurs during mobilization and during transplant-related chemotherapy.
Materials and methods

Patients and chemotherapy protocol
Twenty-one patients with MM who were undergoing PBSC transplant were enrolled into the study. All patients received four consecutive courses of VAD as first line chemotherapy (dexamethazone 40 mg i.v./day for 4 days; vincristine 0.4 mg i.v. by continuous perfusion/day × 4 days and adriamicin 9 mg/m 2 by continuous perfusion/day × 4 days). Afterwards, PBSC mobilization was conducted with high-dose cyclosphosphamide (HD-CY 7 g/m 2 ) plus granulocyte colony-stimulating factor (G-CSF) (5 g/kg/day) from day +2 until the end of leukapheresis collections. Leukaphereses were performed during the recovery phase as soon as the concentration of CD34 + cells in the peripheral blood was Ͼ20 000/ml. PBSC were collected prior to the first transplant. Even in cases of double transplantation there was only one course of PBSC mobilization. Patients were participating in a randomized study comparing the antitumor activity of one vs two autologous transplants in which all underwent at least one transplant and about one third received two transplants. There was a median time of 4 months (range 2-6) between the first and the second transplant. Conditioning therapy for the first PBSC transplant was high-dose melphalan (200 mg/m 2 ) while melphalan (120 mg/m 2 ) and busulphan (12 mg/kg) were used for conditioning prior to the second transplant. All patients received G-CSF (5 g/kg/day) from day +1 after PBSC until the WBC was Ͼ0.5 × 10 9 /l for 3 consecutive days.
CFU-GM colony assay
Briefly, 200 000 mononuclear cells were plated in duplicate in methylcellulose medium, as already reported. 21 
Platelet parameters
Platelet count, RP and GC plasma level were monitored. The platelet parameters were studied in patients during the mobilizing regimen (group I) and during the first (group II) and second transplant (group III).
Platelet count: Whole blood was collected into tubes containing EDTA. Cell counts were performed by an automatic electronic counter (JT Coulter, Hialeah, FL, USA) and confirmed by microscopic study when the platelet count was Ͻ30 × 10 9 /l. Platelet counts were monitored from day 0 (the day before starting the mobilizing regimen or conditioning therapy for transplants) to day +16.
Reticulated platelets: Platelet-rich plasma of EDTA blood samples was prepared by centrifugation at 200 g for 10 min. After washing in citrate glucose EDTA buffer, a final concentration of platelets at 10 × 10 9 /l was obtained in the buffer. A 50 l aliquot of platelet suspension was incubated with 450 l thiazole orange (TO) (Reticcount; Beckton Dickinson, San Jose, CA, USA) at room temperature for 1 h in darkness. Immediately after incubation, fluorescence analysis was performed on a flow cytometer. In each sample, 10 000 platelets were analyzed, the percentage of RP recorded, and the absolute number of RP was calculated by using the percentage and platelet count. The analysis of TO labeling was done as proposed by Ault et al. 6 Briefly, RP were calculated by measuring both forward light scatter and green (540 nm) fluorescence using logarithmic amplification. A plot of forward light scatter vs fluorescence was generated and large platelets containing more nucleic acid were assumed to represent RP. To define fluorescence positivity, a control sample stained with TO was employed and a marker was set with 99% of the platelets below this threshold. A minimum of three samples from normal volunteers was run each week. As with platelet counts, RP were assessed from day 0 to day +16.
Glycocalicin assay
Plasma GC concentrations were measured by a commercially available EIA kit (Glycocalicin EIA Kit; Takara Biomedical, Japan). Citrated samples were collected and plasma was separated by centrifugation (1000 g for 15 min at 4°C). Then, plasma samples were frozen at −20°C until the assay was performed. GC index (GCI) was also calculated. GCI is glycocalicin normalized for the individual platelet count: GC × (250 × 10 6 /ml)/individual platelet count, as proposed by Steinberg et al. 18 The GC plasma level was assessed in the three groups of patients at the following times: prior to chemotherapy, at the time of the platelet nadir and during platelet recovery (day +14 or +16).
Statistical analysis
The results are expressed as the mean or the mean Ϯ standard deviation. Variance within the group of patients was calculated using a statistical software package (SOLO)
Results
The median number of CD34
+ cells infused at the first transplant was 5.8 × occurred after 10-12 days from the beginning of therapy, both after HD-CY and after transplant-related chemotherapy. Patients began to show recovery of their platelet count between day +12 and day +16 following chemotherapy. They were discharged during the time course of the study, as they became transfusion independent. The median platelet number after 2 months from the first and second transplant was 163 × 10 9 /l (range 128-212) and 181 × 10 9 /l (range 118-245), respectively. The percentage of platelets with a high RNA count, also referred to as RP was 1.2 Ϯ 0.6 for the normal control group. The mean percentage of RP in the three groups of patients was within the normal range at baseline time ( Figure 2) . Unexpectedly, the mean percentage of RP following HD-CY rose until day 8 and then gradually decreased (Figure 2 ; F 2.68; P Ͻ 0.04). At variance, the mean percentage of RP reached its nadir on day +10 and then gradually increased after the first and second PBSC transplant ( Figure 2 ). It is noteworthy that the percentage of RP was always higher after the first transplant in comparison to that observed at the second PBSC infusion, even though the difference between the two groups was significant only from day +12 (P Ͻ 0.03). The maximum percentage of RP was reached between days +14 and +16.
The mean GC value of 46 normal donors was 853 Ϯ 310 ng/ml. Patients treated with HD-CY showed a mean value of plasma GC (693 Ϯ 265 ng/ml) which was not significantly different from normal control values. However, a significant decrease of GC (479 Ϯ 193 ng/ml; P Ͻ 0.02) was observed at the time of the platelet nadir. In the early phase of platelet recovery, the mean GC plasma level increased slightly to 624 Ϯ 230 ng/ml, but always remained lower than that observed in normal controls (P Ͻ 0.05). GC concentration was not significantly different from that observed in normal controls throughout the period of observation in patients undergoing either first or second transplant. GCI values of the three groups at baseline time were not significantly different from those observed in normal controls. However, at the time of the platelet nadir, a significant increase of GCI was observed in the three groups in comparison with that documented at baseline time (P Ͻ 0.002). Patients undergoing HD-CY showed a GCI significantly (P Ͻ 0.04) reduced in comparison with those observed after either first or second transplant. During platelet recovery, a marked reduction in GCI was observed in all three groups, the most pronounced decrease being in patients undergoing HD-CY (Figure 3) .
Discussion
In the present study, thrombocytopoiesis of MM patients undergoing single or double transplants was characterized by measuring the level of RP and plasma GC.
Our results suggest that the conditioning regimen induces a marked reduction of RP (both percentage and absolute value) after single or double transplant, while the regimen employed for PBSC mobilization induces a significant increase in RP (percentage), the maximum mean level of which corresponds to the platelet nadir. The increase in reticulated platelets (percentage) after mobilization for PBSC collection may contribute to the faster platelet recovery observed after transplantation of mobilized PBSC 10 in comparison with that reported after infusion of marrow cells. Furthermore, the observation that platelet recovery occured after double transplantation demonstrates that thrombopoietic capacity is retained despite the additional burden of the second transplant. Finally, since the absolute number of reticulated platelets was always very low, we did not find any significant correlation between the number of CD34
+ cells × 10 6 /kg or CFU-GM × 10 4 /kg and the number of reticulated platelets at the time of the platelet nadir.
Since plasma GC is influenced by platelet number, the GCI represents a useful parameter for assessing platelet damage and turnover. We found that prior to chemotherapy no platelet damage or increased platelet turnover was observable in any of the three groups of patients. By contrast, at platelet nadir time, increased platelet damage was observed in all three groups and this pattern was more pronounced after the first and second transplant. It has also been suggested that GCI provide information about platelet life-span and that this could correlate with the inverse of the value for platelet survival. 18 We observed increased platelet turnover at platelet nadir time. Both transplanted groups showed greater platelet damage than did the HD-CY group. Increased platelet damage was also observed during platelet recovery, after either first or second transplant. The effect of platelet transfusion on glycocalicin level and index was irrelevant at the time of the platelet nadir since the samples for glycocalicin evaluation were always collected before platelet transfusions. The same parameters are slightly influenced by transfusion therapy during the recovery phase (days +14-16), as the majority of the patients received platelet support on days +10-12 and the protein half-life was calculated to be 2.5 to 5 days. 16 Furthermore, despite the fact that the three groups of patients received roughly the same platelet support, the mean GCI value was higher after first or second transplant than after mobilization. This study thus highlights the utility of GC as a parameter for assessing platelet damage and suggests that chemotherapyrelated thrombocytopenia has a dual mechanism: that is to say that thrombocytopenia results from decreased platelet production in combination with increased platelet damage and possible destruction. It is still unclear whether platelet damage is due to a direct effect of chemotherapy on platelets or to an effect on other cells (eg endothelial cells) which may activate or damage platelets.
